Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

August 20, 2026 - 02:12

Longeveron Inc. has announced the appointment of Nirav Jhaveri as its new Chief Financial Officer, effective immediately. The clinical stage biotechnology company, which focuses on cellular therapies for rare pediatric and aging-related conditions, confirmed the leadership change on Wednesday.

Jhaveri brings more than 25 years of experience in capital markets, corporate finance, business development, and investor relations to the role. Over 15 of those years were spent specifically within the biotech sector, giving him a deep understanding of the financial challenges and opportunities facing clinical stage companies.

In his new position, Jhaveri will oversee all financial operations, including strategic planning, fundraising efforts, and investor communications. His background in capital markets is expected to be a key asset as Longeveron continues to advance its pipeline of investigational therapies through clinical development.

The appointment comes at a critical time for the company, which is actively working to progress its lead product candidate for hypoplastic left heart syndrome and other conditions. The company's leadership expressed confidence that Jhaveri's track record in guiding biotech firms through growth phases will support Longeveron's long-term objectives.

Jhaveri succeeds the previous CFO, and the transition is said to be smooth with no disruption to ongoing operations. The company remains focused on its mission to develop treatments for life-threatening conditions with high unmet medical needs.